HRP20210840T1 - Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci - Google Patents
Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci Download PDFInfo
- Publication number
- HRP20210840T1 HRP20210840T1 HRP20210840TT HRP20210840T HRP20210840T1 HR P20210840 T1 HRP20210840 T1 HR P20210840T1 HR P20210840T T HRP20210840T T HR P20210840TT HR P20210840 T HRP20210840 T HR P20210840T HR P20210840 T1 HRP20210840 T1 HR P20210840T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- pegylated interferon
- oligonucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648711P | 2012-05-18 | 2012-05-18 | |
| US201261695035P | 2012-08-30 | 2012-08-30 | |
| EP13791618.5A EP2849798B1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
| PCT/CA2013/050379 WO2013170386A1 (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210840T1 true HRP20210840T1 (hr) | 2021-08-06 |
Family
ID=49581470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210840TT HRP20210840T1 (hr) | 2012-05-18 | 2013-05-17 | Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9492506B2 (https=) |
| EP (1) | EP2849798B1 (https=) |
| JP (1) | JP2015517504A (https=) |
| KR (1) | KR102068109B1 (https=) |
| CN (1) | CN104349793B (https=) |
| AU (1) | AU2013262416B2 (https=) |
| BR (1) | BR112014028654A2 (https=) |
| CA (1) | CA2873529C (https=) |
| CL (1) | CL2014003134A1 (https=) |
| CO (1) | CO7131387A2 (https=) |
| CR (1) | CR20140527A (https=) |
| CY (1) | CY1124345T1 (https=) |
| DK (1) | DK2849798T3 (https=) |
| DO (1) | DOP2014000264A (https=) |
| EA (1) | EA035967B1 (https=) |
| EC (1) | ECSP14027694A (https=) |
| ES (1) | ES2873844T3 (https=) |
| HR (1) | HRP20210840T1 (https=) |
| HU (1) | HUE054875T2 (https=) |
| IL (1) | IL235548B (https=) |
| LT (1) | LT2849798T (https=) |
| MX (1) | MX346239B (https=) |
| MY (1) | MY168778A (https=) |
| NZ (1) | NZ703095A (https=) |
| PH (1) | PH12014502551B1 (https=) |
| PL (1) | PL2849798T3 (https=) |
| PT (1) | PT2849798T (https=) |
| RS (1) | RS62030B1 (https=) |
| SG (1) | SG11201407599SA (https=) |
| SI (1) | SI2849798T1 (https=) |
| SM (1) | SMT202100319T1 (https=) |
| TW (1) | TWI635864B (https=) |
| WO (1) | WO2013170386A1 (https=) |
| ZA (1) | ZA201408674B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943591B2 (en) | 2007-05-11 | 2011-05-17 | Adynxx, Inc. | Gene expression and pain |
| PT2846839T (pt) | 2012-05-10 | 2019-05-29 | Adynxx Inc | Formulações para a administração de ingredientes ativos |
| SG11201501255PA (en) * | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| CN106659730A (zh) | 2014-07-10 | 2017-05-10 | 里普利科股份有限公司 | 治疗b型肝炎和d型肝炎病毒感染的方法 |
| RU2017108238A (ru) | 2014-08-15 | 2018-09-17 | Эйдинкс, Инк. | Олигонуклеотиды-приманки для лечения боли |
| PE20211783A1 (es) * | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| EP4728073A1 (en) * | 2023-06-16 | 2026-04-22 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2769114B2 (ja) * | 1993-10-29 | 1998-06-25 | サイクローン・ファーマシューティカルズ | ミニマルｂ型肝炎感染症治療用医薬組成物 |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| BR0314236A (pt) * | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| CA2516552A1 (en) * | 2003-02-26 | 2004-09-10 | Intermune, Inc. | Polyethylene glycol modified interferon compositions and methods of use thereof |
| JP2007509950A (ja) * | 2003-10-27 | 2007-04-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ処置の組合せ剤 |
| CA2584207A1 (en) * | 2004-10-19 | 2006-04-27 | Replicor, Inc. | Antiviral oligonucleotides |
| WO2007022642A2 (en) * | 2005-08-25 | 2007-03-01 | Replicor Inc. | Anti-inflammatory molecules and their uses |
| EP1928498A4 (en) * | 2005-09-29 | 2009-11-11 | Cell Biosciences Inc S | METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF |
| US20090215873A1 (en) | 2005-09-29 | 2009-08-27 | Andrew Vaillant | Therapeutic Molecules and their Uses |
| GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
| NZ585784A (en) * | 2007-12-13 | 2012-09-28 | Alnylam Pharmaceuticals Inc | siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection |
| CA2717792A1 (en) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| KR101704988B1 (ko) * | 2009-05-28 | 2017-02-08 | 큐알엔에이, 인크. | 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료 |
| BR112012008865A2 (pt) * | 2009-10-16 | 2019-09-24 | Glaxo Group Ltd | inibidores de hbv anti-sentido. |
| BR112013003875B1 (pt) | 2010-08-20 | 2021-10-05 | Replicor Inc | Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos |
| SG11201501255PA (en) | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
-
2013
- 2013-05-17 SM SM20210319T patent/SMT202100319T1/it unknown
- 2013-05-17 JP JP2015511877A patent/JP2015517504A/ja active Pending
- 2013-05-17 HR HRP20210840TT patent/HRP20210840T1/hr unknown
- 2013-05-17 EP EP13791618.5A patent/EP2849798B1/en active Active
- 2013-05-17 TW TW102117594A patent/TWI635864B/zh not_active IP Right Cessation
- 2013-05-17 WO PCT/CA2013/050379 patent/WO2013170386A1/en not_active Ceased
- 2013-05-17 SI SI201331881T patent/SI2849798T1/sl unknown
- 2013-05-17 MX MX2014014021A patent/MX346239B/es active IP Right Grant
- 2013-05-17 LT LTEP13791618.5T patent/LT2849798T/lt unknown
- 2013-05-17 NZ NZ703095A patent/NZ703095A/en unknown
- 2013-05-17 RS RS20210674A patent/RS62030B1/sr unknown
- 2013-05-17 DK DK13791618.5T patent/DK2849798T3/da active
- 2013-05-17 AU AU2013262416A patent/AU2013262416B2/en active Active
- 2013-05-17 ES ES13791618T patent/ES2873844T3/es active Active
- 2013-05-17 MY MYPI2014003189A patent/MY168778A/en unknown
- 2013-05-17 US US13/896,510 patent/US9492506B2/en active Active
- 2013-05-17 CA CA2873529A patent/CA2873529C/en active Active
- 2013-05-17 CN CN201380026009.3A patent/CN104349793B/zh active Active
- 2013-05-17 PL PL13791618T patent/PL2849798T3/pl unknown
- 2013-05-17 EA EA201401278A patent/EA035967B1/ru unknown
- 2013-05-17 PT PT137916185T patent/PT2849798T/pt unknown
- 2013-05-17 KR KR1020147035252A patent/KR102068109B1/ko active Active
- 2013-05-17 SG SG11201407599SA patent/SG11201407599SA/en unknown
- 2013-05-17 HU HUE13791618A patent/HUE054875T2/hu unknown
- 2013-05-17 BR BR112014028654A patent/BR112014028654A2/pt active Search and Examination
-
2014
- 2014-11-06 IL IL235548A patent/IL235548B/en active IP Right Grant
- 2014-11-14 PH PH12014502551A patent/PH12014502551B1/en unknown
- 2014-11-18 EC ECIEPI201427694A patent/ECSP14027694A/es unknown
- 2014-11-18 DO DO2014000264A patent/DOP2014000264A/es unknown
- 2014-11-18 CR CR20140527A patent/CR20140527A/es unknown
- 2014-11-18 CL CL2014003134A patent/CL2014003134A1/es unknown
- 2014-11-19 CO CO14254322A patent/CO7131387A2/es unknown
- 2014-11-25 ZA ZA2014/08674A patent/ZA201408674B/en unknown
-
2021
- 2021-05-31 CY CY20211100467T patent/CY1124345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210840T1 (hr) | Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci | |
| De Clercq | Antivirals: past, present and future | |
| AR079555A1 (es) | Metodos de tratamiento de la infeccion de virus de hepatitis b (hbv) y virus de hepatitis c (hcv) | |
| JP2017521433A5 (https=) | ||
| ME02321B (me) | Antivirusna jedinjenja | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| JP2015517504A5 (https=) | ||
| HRP20211448T1 (hr) | Alfa4beta7 integrin tioeter peptidni antagonisti | |
| JP2013521279A5 (https=) | ||
| JP2013510904A5 (https=) | ||
| CN103906759A (zh) | 用于治疗病毒感染的化合物和药物组合物 | |
| JP2015528449A5 (https=) | ||
| BR112014003420A2 (pt) | hemifumarato de tenofovir alafenamida | |
| De Clercq | Antiviral drug discovery: ten more compounds, and ten more stories (part B) | |
| ES2572329A2 (es) | Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc | |
| NZ762994A (en) | Hepatitis b antiviral agents | |
| BR112013024809A2 (pt) | tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas | |
| EA201790786A1 (ru) | Комбинированная терапия вызываемой вирусами hbv и hdv инфекции | |
| IN2014DN09963A (https=) | ||
| JP2016128507A5 (https=) | ||
| HRP20191723T1 (hr) | Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa | |
| De Clercq | The Holý Trinity: the acyclic nucleoside phosphonates | |
| JP2014532722A5 (https=) | ||
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| EA201401148A1 (ru) | Биологически активные пептидные комплексы |